About: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 25 February 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в лютому 2009 (uk) scientific article published on 25 February 2009 (en) مقالة علمية نشرت في 25 فبراير 2009 (ar)
publication date	wds:Q37205038-294F59AA-21A5-4983-811E-8C970CB887BC
publication date	2009-02-25 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37205038-1B582859-A1FD-4962-B910-B029775A77B8
language of work or name	English
exact match	wds:Q37205038-51C739F0-E4BE-4F68-A72A-444F95F895BC
exact match	https://scigraph.springernature.com/pub.10.1186/1824-7288-35-4
cites work	wds:Q37205038-20B80865-8967-4267-A098-C65EC72671A6 wds:Q37205038-20EAC568-9133-4D40-9B08-63BE41E9A59F wds:Q37205038-360BF1D0-91B3-447A-9B47-39E0749215F5 wds:Q37205038-420A21EF-6503-41F1-BB17-78A112BEFF45 wds:Q37205038-49A96970-50C0-4186-A950-8B7D6145762A wds:Q37205038-4B42F3B8-A97B-44AB-B40F-BA6890530182 wds:Q37205038-4BEE4FCC-C86D-4844-8C14-51DB72A5280F wds:Q37205038-6159CABF-6B95-4778-BC0D-950EBA6FBE30 wds:Q37205038-63DDCFE9-277D-46B9-AD27-72DB3B4531AC wds:Q37205038-7CD2F274-F9C2-4E35-A547-03107015141D wds:Q37205038-81A46BC9-87F9-48E5-951F-808273AD4392 wds:Q37205038-8469E25B-AD7B-4C7C-BD04-11D5778B4E93 wds:Q37205038-AC6AA728-5018-447D-A9AC-F2B728E7AF8F wds:Q37205038-B03F86E4-B6BC-4188-AA32-A39562212C49 wds:Q37205038-B4585618-6EC6-4135-BC57-B84A10218B59 wds:Q37205038-B6ED5847-C153-4C15-8DA5-4A71D2CA5111 wds:Q37205038-BAE6EC95-1DE4-49F3-B6B4-2507CD3687A0 wds:Q37205038-CFB31F9C-BBB9-4C1F-9057-1EEB2BAE156D wds:Q37205038-D9AB39D8-92F2-4854-808E-1B3531782944 wds:Q37205038-E05213AB-07ED-4343-AC8B-E624918C8F32 wds:Q37205038-E226C58E-F497-4AD5-B769-96733AC4E5B7 wds:Q37205038-F982DC70-4FE4-45CD-995F-CDAFC373A070
cites work	Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2 Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996) Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds Respiratory syncytial virus infection Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group Five-hundred life-saving interventions and their cost-effectiveness The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection Respiratory morbidity 20 years after RSV infection in infancy [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]
author name string	wds:Q37205038-3EF4C756-BA2C-403F-98E7-C6FC94F59E89 wds:Q37205038-DA9B9547-46F3-478B-BF48-5A791892D33E wds:Q37205038-E83B8BC2-7026-4447-A1AE-BF68D90FE355
author name string	Roberto Ravasio Gaetano Chirico Urbano Sbarigia
rdfs:label	Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (nl) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (en) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (ast)
skos:prefLabel	Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (nl) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (en) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (ast)
name	Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (nl) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (en) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (ast)
title	wds:Q37205038-42962720-8E37-4AAE-8255-62EA95499B68
title	Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (en)
page(s)	wds:Q37205038-7D88739D-919C-4C35-826C-88D9139A82F3
page(s)	4
instance of	wds:Q37205038-B111E2E6-2663-4108-B410-4732104A9D8B
instance of	scholarly article
main subject	wds:Q37205038-F46109D4-6883-4392-BBDB-7159956868F2 wds:Q37205038-F4828E63-C1D6-4ACB-8DF7-F562630703A9
main subject	Italy preterm infant
PubMed ID	wds:Q37205038-927A8376-B31F-407A-B268-427ADDF25208
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19490659
PubMed ID	19490659
published in	wds:Q37205038-8631C5DF-E99C-4E9F-8FD2-171C83CF0EDB
published in	Italian Journal of Paediatrics
issue	wds:Q37205038-394DC801-41A5-4FC0-9DA2-ECA34F88034A
volume	wds:Q37205038-1FAA5171-B6FD-4E72-96FE-8B643DA0B334
issue	1

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software